Satellos Bioscience Inc. (NASDAQ:MSLE - Free Report) - Research analysts at HC Wainwright dropped their FY2026 earnings per share (EPS) estimates for Satellos Bioscience in a report issued on Friday, November 13th. HC Wainwright analyst A. He now anticipates that the company will post earnings per share of ($2.01) for the year, down from their previous forecast of ($1.92). HC Wainwright currently has a "Buy" rating and a $18.00 target price on the stock. The consensus estimate for Satellos Bioscience's current full-year earnings is ($1.86) per share. HC Wainwright also issued estimates for Satellos Bioscience's Q4 2026 earnings at ($0.39) EPS, Q1 2027 earnings at ($0.42) EPS, Q2 2027 earnings at ($0.45) EPS, Q3 2027 earnings at ($0.47) EPS, Q4 2027 earnings at ($0.49) EPS, FY2027 earnings at ($1.85) EPS, FY2028 earnings at ($1.84) EPS, FY2029 earnings at ($0.86) EPS and FY2030 earnings at $0.87 EPS.
Satellos Bioscience (NASDAQ:MSLE - Get Free Report) last issued its quarterly earnings data on Thursday, November 12th. The company reported ($0.53) earnings per share for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.09).
Several other equities analysts also recently weighed in on the company. Wall Street Zen raised Satellos Bioscience from a "strong sell" rating to a "sell" rating in a research report on Saturday. Zacks Research cut shares of Satellos Bioscience from a "hold" rating to a "strong sell" rating in a research report on Wednesday, October 21st. Weiss Ratings reissued a "sell (d-)" rating on shares of Satellos Bioscience in a research report on Wednesday, November 4th. Finally, Craig Hallum started coverage on shares of Satellos Bioscience in a research note on Thursday, October 8th. They issued a "buy" rating and a $24.00 price objective for the company. Six investment analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, Satellos Bioscience currently has a consensus rating of "Moderate Buy" and a consensus price target of $20.60.
Read Our Latest Analysis on MSLE
Satellos Bioscience Trading Down 2.4%
MSLE opened at $6.47 on Tuesday. The stock's 50-day moving average price is $7.72 and its 200 day moving average price is $8.18. Satellos Bioscience has a 12-month low of $5.44 and a 12-month high of $13.39. The firm has a market cap of $137.29 million, a price-to-earnings ratio of -3.10 and a beta of 1.63.
Institutional Trading of Satellos Bioscience
A hedge fund recently raised its position in Satellos Bioscience stock. Stonepine Capital Management LLC lifted its stake in Satellos Bioscience Inc. (NASDAQ:MSLE - Free Report) by 391.6% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 491,624 shares of the company's stock after purchasing an additional 391,624 shares during the period. Satellos Bioscience comprises about 0.0% of Stonepine Capital Management LLC's holdings, making the stock its 16th largest holding. Stonepine Capital Management LLC owned about 2.36% of Satellos Bioscience worth $3,723,291 as of its most recent filing with the Securities and Exchange Commission.
Trending Headlines about Satellos Bioscience
These are some of the MSLE headlines that stood out recently:
- Positive Sentiment: HC Wainwright raised its estimates for several future periods, including FY2027–FY2029, and now projects a profit of $0.87 per share in FY2030. It maintained its Buy rating and $18 price target. Satellos Bioscience coverage
- Negative Sentiment: The analyst lowered its FY2026 forecast to a loss of $2.01 per share from $1.92, while continuing to expect losses in FY2027–FY2029. That points to ongoing expenses and uncertainty before the projected return to profitability. Satellos Bioscience coverage
About Satellos Bioscience
(
Get Free Report)
Satellos Bioscience is a biotechnology company developing treatments intended to improve the body's ability to repair and regenerate muscle. Its research focuses on muscle stem cells and the cellular processes that guide their function. The company's lead program, SAT-3247, is an investigational oral small-molecule therapy being developed for Duchenne muscular dystrophy. Satellos is studying whether its approach can restore muscle stem-cell activity and support muscle regeneration; the candidate remains in development and is not an approved treatment.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Satellos Bioscience, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Satellos Bioscience wasn't on the list.
While Satellos Bioscience currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.